|
1
|
Kodama J, Seki N, Masahiro S, Kusumoto T,
Nakamura K, Hongo A and Hiramatsu Y: Prognostic factors in stage
IB-IIB cervical adenocarcinoma patients treated with radical
hysterectomy and pelvic lymphadenectomy. J Surg Oncol. 101:413–417.
2010.PubMed/NCBI
|
|
2
|
Noordhuis MG, Fehrmann RS, Wisman GB,
Nijhuis ER, van Zanden JJ, Moerland PD, Ver Loren van Themaat E,
Volders HH, Kok M, ten Hoor KA, et al: Involvement of the TGF-beta
and beta-catenin pathways in pelvic lymph node metastasis in
early-stage cervical cancer. Clin Cancer Res. 17:1317–1330. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Perez DS, Hoage TR, Pritchett JR,
Ducharme-Smith AL, Halling ML, Ganapathiraju SC, Streng PS and
Smith DI: Long, abundantly expressed non-coding transcripts are
altered in cancer. Hum Mol Genet. 17:642–655. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guttman M, Donaghey J, Carey BW, Garber M,
Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, et al:
lincRNAs act in the circuitry controlling pluripotency and
differentiation. Nature. 477:295–300. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rinn JL, Kertesz M, Wang JK, Squazzo SL,
Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, et
al: Functional demarcation of active and silent chromatin domains
in human HOX loci by non-coding RNAs. Cell. 129:1311–1323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long non-coding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hung T, Wang Y, Lin MF, Koegel AK, Kotake
Y, Grant GD, Horlings HM, Shah N, Umbricht C, Wang P, et al:
Extensive and coordinated transcription of non-coding RNAs within
cell-cycle promoters. Nat Genet. 43:621–629. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu C, Wu HT, Zhu N, Shi YN, Liu Z, Ao BX,
Liao DF, Zheng XL and Qin L: Steroid receptor RNA activator:
Biologic function and role in disease. Clin Chim Acta. 459:137–146.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan R, Wang K, Peng R, Wang S, Cao J, Wang
P and Song C: Genetic variants in lncRNA SRA and risk of breast
cancer. Oncotarget. 7:22486–22496. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hussein-Fikret S and Fuller PJ: Expression
of nuclear receptor coregulators in ovarian stromal and epithelial
tumours. Mol Cell Endocrinol. 229:149–160. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cooper C, Guo J, Yan Y,
Chooniedass-Kothari S, Hube F, Hamedani MK, Murphy LC, Myal Y and
Leygue E: Increasing the relative expression of endogenous
non-coding steroid receptor RNA activator (SRA) in human breast
cancer cells using modified oligonucleotides. Nucleic Acids Res.
37:4518–4531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Colley SM and Leedman PJ: Steroid Receptor
RNA Activator - A nuclear receptor coregulator with multiple
partners: Insights and challenges. Biochimie. 93:1966–1972. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cooper C, Vincett D, Yan Y, Hamedani MK,
Myal Y and Leygue E: Steroid Receptor RNA Activator bi-faceted
genetic system: Heads or Tails? Biochimie. 93:1973–1980. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carninci P, Kasukawa T, Katayama S, Gough
J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, et al:
RIKEN Genome Exploration Research Group and Genome Science Group
(Genome Network Project Core Group): The transcriptional landscape
of the mammalian genome. Science. 309:1559–1563. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morris KV and Vogt PK: Long antisense
non-coding RNAs and their role in transcription and oncogenesis.
Cell Cycle. 9:2544–2547. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dinger ME, Amaral PP, Mercer TR, Pang KC,
Bruce SJ, Gardiner BB, Askarian-Amiri ME, Ru K, Soldà G, Simons C,
et al: Long non-coding RNAs in mouse embryonic stem cell
pluripotency and differentiation. Genome Res. 18:1433–1445. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hall PA and Russell SH: New perspectives
on neoplasia and the RNA world. Hematol Oncol. 23:49–53. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote
cancer metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim HJ, Lee DW, Yim GW, Nam EJ, Kim S, Kim
SW and Kim YT: Long non-coding RNA HOTAIR is associated with
human cervical cancer progression. Int J Oncol. 46:521–530. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim HJ, Eoh KJ, Kim LK, Nam EJ, Yoon SO,
Kim KH, Lee JK, Kim SW and Kim YT: The long non-coding RNA
HOXA11 antisense induces tumor progression and stemness
maintenance in cervical cancer. Oncotarget. 7:83001–83016. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Curran S and Murray GI: Matrix
metalloproteinases: Molecular aspects of their roles in tumour
invasion and metastasis. Eur J Cancer. 36:1621–1630. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Biewenga P, van der Velden J, Mol BW,
Stalpers LJ, Schilthuis MS, van der Steeg JW, Burger MP and Buist
MR: Prognostic model for survival in patients with early stage
cervical cancer. Cancer. 117:768–776. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carmeliet P: VEGF as a key mediator of
angiogenesis in cancer. Oncology. 69 Suppl 3:S4–S10. 2005.
View Article : Google Scholar
|
|
24
|
Burger RA: Role of vascular endothelial
growth factor inhibitors in the treatment of gynecologic
malignancies. J Gynecol Oncol. 21:3–11. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ramis-Conde I, Chaplain MA, Anderson AR
and Drasdo D: Multi-scale modelling of cancer cell intravasation:
The role of cadherins in metastasis. Phys Biol. 6:0160082009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Morin PJ: beta-catenin signaling and
cancer. BioEssays. 21:1021–1030. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Martin TA, Goyal A, Watkins G and Jiang
WG: Expression of the transcription factors snail, slug, and twist
and their clinical significance in human breast cancer. Ann Surg
Oncol. 12:488–496. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Calaf GM, Balajee AS, Montalvo-Villagra
MT, Leon M, Daniela NM, Alvarez RG, Roy D, Narayan G and
Abarca-Quinones J: Vimentin and Notch as biomarkers for breast
cancer progression. Oncol Lett. 7:721–727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Artavanis-Tsakonas S, Rand MD and Lake RJ:
Notch signaling: Cell fate control and signal integration in
development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Timmerman LA, Grego-Bessa J, Raya A,
Bertrán E, Pérez-Pomares JM, Díez J, Aranda S, Palomo S, McCormick
F, Izpisúa-Belmonte JC, et al: Notch promotes
epithelial-mesenchymal transition during cardiac development and
oncogenic transformation. Genes Dev. 18:99–115. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Z, Banerjee S, Li Y, Rahman KM, Zhang
Y and Sarkar FH: Down-regulation of notch-1 inhibits invasion by
inactivation of nuclear factor-kappaB, vascular endothelial growth
factor, and matrix metalloproteinase-9 in pancreatic cancer cells.
Cancer Res. 66:2778–2784. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nair P, Somasundaram K and Krishna S:
Activated Notch1 inhibits p53-induced apoptosis and sustains
transformation by human papillomavirus type 16 E6 and E7 oncogenes
through a PI3K-PKB/Akt-dependent pathway. J Virol. 77:7106–7112.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Masuda S, Kumano K, Shimizu K, Imai Y,
Kurokawa M, Ogawa S, Miyagishi M, Taira K, Hirai H and Chiba S:
Notch1 oncoprotein antagonizes TGF-beta/Smad-mediated cell growth
suppression via sequestration of co-activator p300. Cancer Sci.
96:274–282. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Klinakis A, Szabolcs M, Politi K, Kiaris
H, Artavanis-Tsakonas S and Efstratiadis A: Myc is a Notch1
transcriptional target and a requisite for Notch1-induced mammary
tumorigenesis in mice. Proc Natl Acad Sci USA. 103:9262–9267. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu ZH, Dai XM and Du B: Hes1: A key role
in stemness, metastasis and multidrug resistance. Cancer Biol Ther.
16:353–359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oswald F, Täuber B, Dobner T, Bourteele S,
Kostezka U, Adler G, Liptay S and Schmid RM: p300 acts as a
transcriptional co-activator for mammalian Notch-1. Mol Cell Biol.
21:7761–7774. 2001. View Article : Google Scholar : PubMed/NCBI
|
